New heart valve device shows promise in early trial
NCT ID NCT06680427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new device called the Siegel TAVR system to replace a narrowed heart valve in 30 adults aged 50 and older with severe aortic stenosis. The goal is to see if the device can be safely implanted and improve blood flow without major complications. Participants will be followed for 30 days to check for death, disabling stroke, or need for additional procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS SYMPTOMATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90071, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center/ NYPH
New York, New York, 10032, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NCH Healthcare System
Naples, Florida, 34102, United States
-
Piedmont Healthcare
Atlanta, Georgia, 30309, United States
-
Stanford
Palo Alto, California, 94304, United States